Four things to know about the company’s second-quarter financial performance:
- Medtronic saw a 3 percent dip in reported revenue, but saw a 2 percent increase in organic growth.
- Medtronic brought in $2.19 billion from its neuroscience portfolio
- The company reported a GAAP diluted earnings per share of $0.32, a decrease of 67 percent, and a non-GAAP diluted earnings per share of $1.30, a decrease of 2 percent.
- The company said in a Nov. 22 news release that it expects to see more organic revenue growth during the second half of the fiscal year.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
